CoChat

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis

Open access
Sanyal, Arun J., Shankar, Sudha S., Yates, Katherine P., Bolognese, James, Daly, Erika, Dehn, Clayton A., Neuschwander-Tetri, Brent, Kowdley, Kris, Vuppalanchi, Raj, Behling, Cynthia, Tonascia, James, Samir, Anthony, Sirlin, Claude, Sherlock, Sarah P., Fowler, Kathryn, Heymann, Helen, Kamphaus, Tania N., Loomba, Rohit, Calle, Roberto A. · 2023 · Nature Medicine
Cited by 131

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

There are no approved diagnostic biomarkers for at-risk non-alcoholic steatohepatitis (NASH), defined by the presence of NASH, high histological activity and fibrosis stage ≥2, which is associated with higher incidence of liver-related events and mortality. FNIH-NIMBLE is a multi-stakeholder project to support regulatory approval of NASH-related biomarkers. The diagnostic performance of five blood-based panels was evaluated in an observational (NASH CRN DB2) cohort ( n = 1,073) with full spectrum of non-alcoholic fatty liver disease (NAFLD). The panels were intended to diagnose at-risk NASH (NIS4), presence of NASH (OWLiver) or fibrosis stages >2, >3 or 4 (enhanced liver fibrosis (ELF) test, PROC3 and FibroMeter VCTE). The prespecified performance metric was an area under the receiver operating characteristic curve (AUROC) ≥0.7 and superiority over alanine aminotransferase for disease activity and the FIB-4 test for fibrosis severity. Multiple biomarkers met these metrics. NIS4 had an AUROC of 0.81 (95% confidence interval: 0.78–0.84) for at-risk NASH. The AUROCs of the ELF test, PROC3 and FibroMeterVCTE for clinically significant fibrosis (≥stage 2), advanced fibrosis (≥stage 3) or cirrhosis (stage 4), respectively, were all ≥0.8. ELF and FibroMeter VCTE outperformed FIB-4 for all fibrosis endpoints. These data represent a milestone toward qualification of several biomarker panels for at-risk NASH and also fibrosis severity in individuals with NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02539-6

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 131

Metadata

Authors
Sanyal, A. J., Shankar, S. S., Yates, K. P., Bolognese, J., Daly, E., Dehn, C. A., Neuschwander-Tetri, B., Kowdley, K., Vuppalanchi, R., Behling, C., Tonascia, J., Samir, A., Sirlin, C., Sherlock, S. P., Fowler, K., Heymann, H., Kamphaus, T. N., Loomba, R., & Calle, R. A.
Venue
Nature Medicine
Published
2023-09-07
Volume
29
Issue
10
Pages
2656-2664
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4386498686
Cited by
131
References
12
FWCI
21.57
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. https://app.cochat.ai/papers/10.1038/s41591-023-02539-6
The paper
Sanyal, A. J., Shankar, S. S., Yates, K. P., Bolognese, J., Daly, E., Dehn, C. A., Neuschwander-Tetri, B., Kowdley, K., Vuppalanchi, R., Behling, C., Tonascia, J., Samir, A., Sirlin, C., Sherlock, S. P., Fowler, K., Heymann, H., Kamphaus, T. N., Loomba, R., & Calle, R. A. (2023). Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nature Medicine. https://doi.org/10.1038/s41591-023-02539-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.